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Chromones and xanthones are oxygen-containing heterocyclic compounds with bioactive 
properties widely reported in the literature, specially concerning to their antioxidant 
properties. The search for new natural and synthetic chromone and xanthone derivatives order 
to evaluate and discover new structural features rendering optimized biological effects has 
been a challenge. Thus, the aim of this work was to evaluate the scavenging activity of 
reactive oxygen (ROS) and nitrogen (RNS) species of new synthetic hydroxylated chromones 
and xanthones (Fig. 1) using in vitro non-cellular systems. These compounds exhibited 
scavenger effects dependent on the concentration, with IC50 values found at the micromolar 
range. The overall scavenging activity of chromones was better than xanthones, specially the 
one of chromone 3A. In conclusion, the novel tested chromone and xanthone scaffolds proved 





















Figure 1: Chemical structures of the tested compounds.  
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